Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a spinal implant ease chemo pain? new trial aims to find out

NCT ID NCT07579611

Symptom relief Sponsor: Assistance Publique Hopitaux De Marseille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a spinal cord stimulator can reduce chronic nerve pain caused by chemotherapy. 68 adults with pain lasting over a year will have the device implanted and then randomly receive either active or sham stimulation. The goal is to see if active stimulation provides better pain relief than placebo, and to measure effects on quality of life, sleep, and mood.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
spinal cord stimulation device
What this could lead to
If it works, this could offer a new option for people with long-term nerve pain after chemotherapy, when standard painkillers have failed.
What could go wrong
This is a small, early-stage crossover trial with only 68 participants. The sham phase means patients may not benefit during that period, and device implantation carries surgical risks like infection or lead movement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 68 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

May 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult patient with chemotherapy-induced painful neuropathy (platinum salts, vincristine, taxanes, alkaloids, epothilone, thalidomide, etc.) evolving for at least 1 year 2. Indication for spinal cord stimulation validated by a multidisciplinary team meeting according to SFETD/SFNM guidelines 3. Resistance to pharmacological or topical treatment (failure of at least two therapeutic lines or intolerable side effects: anticonvulsants, antidepressants, capsaicin, etc.) 4. Pain score \> 5/10 on numerical scale in the lower limbs 5. Patient able to understand and give informed consent to the protocol 6. Patient affiliated to the French Social Security system 7. Patient able to complete follow-up questionnaires Exclusion Criteria: * 1\. Contraindication to spinal cord stimulation: * Extensive laminectomy * Coagulopathy * Intercurrent infections * Psychiatric disorders 2\. Body Mass Index (BMI) \> 40 3\. Life expectancy \< 1 year 4\. Ongoing pregnancy 5\. Patient under guardianship or curatorship 6\. Patient already implanted with a spinal cord stimulation device

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer-related pain are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cancer Pain chemotherapy-induced neuropathy neuralgia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer-related pain Chemotherapy-induced peripheral neuropathy (CIPN) Neuropathic pain

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hopital de la Timone

    Marseille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.